DLBS1033, A Protein Extract from Lumbricus rubellus, Possesses Antithrombotic and Thrombolytic Activities by Trisina, Jessica et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 519652, 7 pages
doi:10.1155/2011/519652
Research Article
DLBS1033, A Protein Extract from Lumbricusrubellus,
PossessesAntithrombotic andThrombolyticActivities
JessicaTrisina,1 Febrina Sunardi,1 Maggy T. Suhartono,1,2 andRaymondR.Tjandrawinata1
1Division of Protein Biochemistry and Molecular Pharmacology, Dexa Laboratories of Biomolecular Sciences, PT Dexa Medica,
Industri Selatan V Block PP no. 7, Kawasan Industri Jababeka II, Cikarang 17550, Indonesia
2Department of Food Science and Technology, Bogor Agricultural University, Fateta Building Kampus IPB Darmaga,
Bogor 16680, Indonesia
Correspondence should be addressed to Raymond R. Tjandrawinata, raymond@dexa-medica.com
Received 9 November 2010; Revised 17 December 2010; Accepted 15 January 2011
Academic Editor: Michael Kalafatis
Copyright © 2011 Jessica Trisina et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The medicinal value of earthworm has been widely known since the history of Asian ancient medicine. This present study aims
to determine the mechanism of action and eﬀect of a standardized extract of Lumbricus rubellus named as DLBS1033. The
ﬁbrinogen degradation, antiplatelet aggregation, and ex vivo antithrombotic assay using human blood were performed to study
antithrombotic activity. Fibrin plate and clot lysis assay were also done to examine thrombolytic properties. DLBS1033 was found
to possess ﬁbrinogenolytic activity on α-, β-, and γ-chain of ﬁbrinogen. It also induced antiplatelet aggregation and prolonged
blood clotting time, which further conﬁrmed its antithrombotic properties. In addition, thrombolytic properties of DLBS1033
were shown with its fast and long-acting ﬁbrinolytic activity, as well as its eﬀective blood clot lysis activities. In conclusion,
DLBS1033 conferred antithrombotic and thrombolytic action which could be used as a safe and promising oral thrombolytic
drug.
1.Introduction
For several years, earthworms have been widely used in
Indonesia, China, Japan, and the Far East to treat vari-
ous chronic diseases. Deep exploration has been made to
reveal the use of earthworms as antimicrobial [1], anti-
inﬂammatory [2], and anticancer [3] agents.
In 1991, Mihara et al. found that the earthworm from
Lumbricidaefamilycoulddirectlydissolveﬁbrinandactivate
plasminogen [4]. The active constituents of earthworm have
been characterized and known to have ﬁbrinolytic enzymes,
a group of serine protease enzymes. Earthworm ﬁbrinolytic
enzymes (EFEs) are composed of several isozymes which
can be transported into blood through intestinal epithelium
[5–7]. It confers ﬁbrinolytic and ﬁbrinogenolytic properties,
lowers blood viscosity, markedly reduces platelet aggrega-
tion, and promotes thrombus degradation in blood [8–
10]. Due to those properties, earthworm ﬁbrinolytic enzyme
has been extensively studied as an oral thrombolytic drug
[10, 11].
The most common sources of earthworm ﬁbrinolytic
enzymes are Lumbricus rubellus, Eisenia foetida,a n dPhere-
tima sp. Each earthworm has diﬀerent isozyme constituents
depending on the species and living environment [12] that
may lead to diﬀerences in their activities. Recently, research
progresshasbeenmadeusingearthwormasoneofitsnatural
resources in developing medicines to treat thrombosis-
related diseases. It is one of the most widely occurring
diseases in modern life, which often cause disability and
death. This present study was intended to explore the
characterization, activity, and mechanism of actions of
DLBS1033, earthworm extract prepared from Lumbricus
rubellus originated from Indonesia, with regards to its
antithrombotic and thrombolytic activities as a promising
therapeutic agent for thrombosis-associated diseases.
2.MaterialsandMethods
DLBS1033 was prepared in Dexa Laboratories of Biomolec-
ular Sciences (Cikarang, Indonesia). Lumbricus rubellus2 Journal of Biomedicine and Biotechnology
obtained from Pangalengan, West Java, Indonesia, was
extracted using puriﬁed water, followed by continuous
centrifugation (Westfalia, Germany) at room temperature.
Supernatant was then concentrated using rotavapor (B¨ uchi,
Switzerland) and made into powdery form using ﬂuid
bed dryer (Niro, Germany). DLBS1033 was then sterilized
using irradiation with gamma ray at total dose of 10–
12kGy to prevent the bacterial protease contaminating it.
Bovine serum albumin (BSA) fraction V and thrombin
for biochemistry were purchased from Merck (Darmstadt,
Germany). Human ﬁbrinogen fraction I was obtained from
Sigma Aldrich (St. Louis, USA). LMW marker protein was
acquired from Amersham, Bioscience. Other reagents used
were of analytical grade.
2.1. Characterization of DLBS1033
2.1.1. Protein Content and Protease Activity of DLBS1033.
Protein content of DLBS1033 was measured using modiﬁed
Bradford Assay. 100μL of 50mg/mL DLBS1033 in 20mM
potassium phosphate buﬀer were mixed with 2mL of Brad-
fordreagent.Mixturewasincubatedatroomtemperaturefor
5 min, and its absorbance was measured at 595nm.
Protease assay was done to measure the protease activity
of DLBS1033 [13]. 250μL DLBS1033 (50mg/mL) in 20mM
potassium phosphate buﬀer and casein solution were mixed
and incubated at 37◦C for 10min. Reaction was stopped
usingtrichloroaceticacidsolution.Thesolublepeptideswere
then separated from the mixtures using centrifugation. To
develop color, supernatant and Folin’s reagent were mixed
under basic conditions by the addition of Na2CO3 solution.
Themixturewasthenmeasuredforitsabsorbanceat660nm.
The speciﬁc activity was 1180U/mg protein. One unit
was deﬁned as the amount in micromoles of tyrosine
equivalents released from casein per minute at pH 7.5, 37◦C.
The stability of DLBS1033 was also analyzed for its
stability at diﬀerent pH and temperature. The eﬀect of pH
on the activity of DLBS1033 was examined under the range
ofpH2to14.DLBS1033begantoexhibititsproteaseactivity
at pH 4 which gradually increased up to pH 12 (Figure 1).
The activity then dropped drastically at pH 13. Between pH
4 and 12, the optimal activities and stability of DLBS1033
were maintained.
Activity and stability of DLBS1033 were also estimated
based on its activity to degrade casein. The extract was
incubated in various temperatures ranging from 25◦C–80◦C
for 5 hours. The result shows that DLBS1033 gave diﬀerent
response in terms of its protease activity when incubated at
diﬀerent temperatures (Figure 2). The activity of DLBS1033
was lowest at about 0.5–2U/mg when it was incubated at
80◦C. The optimum temperature of DLBS1033 appeared to
be 50◦C, where its activity was still maintained until 5-hour
incubation time.
2.1.2. DLBS1033 Protein Proﬁle. Protein pattern of
DLBS1033 was assayed using SDS PAGE. 12% polyacryl-
amide gel, 15μL DLBS1033 as sample and LMW protein as
ladder were used.
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Figure 1: Stability of DLBS1033 in the range of pH. DLBS1033 was
examined in pH range of 2–14.
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Figure 2: Stability of DLBS1033 in the range of temperature.
DLBS1033 was examined in temperature range of 25◦C–80◦Cf o r
5h o u r s .
The following SDS PAGE shows that DLBS1033 has a
speciﬁc group of proteins as its constituents. As can be seen
inFigure3,theearthwormextractpossesses8majorproteins
with molecular weight below 100kDa. This speciﬁc protein
pattern gives DLBS1033 its unique characteristic, named as
LLP (Lumbricus low molecular-weight proteins).
The speciﬁc proteolytic activity of DLBS1033 LLP
was conﬁrmed with ﬁbrinogen zymography. Zymography
is based on a sodium dodecyl sulfate polyacrylamide
gel impregnated with protein substrate which is later
degraded by the proteases during incubation [14]. 50mg/mL
DLBS1033 in 50mM phosphate buﬀer and native poly-
acrylamide gel 12% containing 1% ﬁbrinogen were used
for the experiment. After electrophoresis, gel was renatured
using 2.5% tween-20 solution for 30min under gentle
agitation and then rinsed in puriﬁed water. The gel was
then incubated with 50mM phosphate buﬀer in 37◦Cf o r
3h. After incubation, it was stained in coomassie blue
staining solution and destained in solution containing
methanol:aceticacid:water(1:1:8,v:v:v).Thepresence
of enzymes with ﬁbrinogenolytic activity was identiﬁed as
clear bands on blue background gel. The result (Figure 4)
showed several clear bands on the zymogram gel indicating
the speciﬁc ﬁbrinogenolytic activity of DLBS1033 LLP.Journal of Biomedicine and Biotechnology 3
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Figure 3: Lumbricus low-molecular-weight protein proﬁle of
DLBS1033. The eathworm extract has 8 major proteins with
molecular weight below 100kDa.
Figure 4:FibrinogenzymogramofDLBS1033.LLPfractionswhich
contributetoﬁbrinogenolyticactivitywereidentiﬁedasclearbands.
Since LLP was a strong ﬁbrinolytic enzyme and impeded
the formation of ﬁbrin, light scattering at 480 nm was used
to assay this enzyme’s activity using chromozym TH as
substrate. Chromozym TH (Tos-Gly-Pro-Arg-4-nitranilide
acetate) is usually used as substrate for the determination
of serine protease in aqueous solution. Initially, 2.8mL
Tris buﬀer and 0.3mL of 1.9mM Chromozym TH were
mixed in a plastic cuvette and the temperature in the
cuvette was maintained at 25◦C. The reaction was then
started by adding 0.1mL of 0.175mg/mL DLBS1033. After
that, the mixture was then observed for its change in
absorbance and ΔA/min wascalculatedfromthe linear range
using the formula: U/mL sample solution: 3.077 × ΔA/min.
Figure 5(a) showed that the absorbance increased gradually
until it reached plateau after 12 minutes. Moreover, the
linear section of changes in absorbance per one minute
(Figure 5(b)) was used to estimate the activity of LLP. The
activity of LLP on Chromozym TH was obtained to be
2.549U/mg.
2.2. Antithrombotic Properties
2.2.1. Fibrinogen Degradation Assay. 12% SDS-PAGE was
used for ﬁbrinogen degradation assay. 500μL ﬁbrino-
gen (5μg/μL ﬁnal concentration) and 500μL DLBS1033
(0.8μg/μL protein concentration) were mixed in 20mM
phosphate buﬀer and incubated at 37◦C. Aliquots were taken
at diﬀerent time intervals for SDS-PAGE analysis. Gel was
stained in coomassie blue solution. Low-molecular-weight
protein marker was used as standard.
2.2.2.AntiplateletAggregationAssay. Thehumanbloodsam-
ples were collected from healthy adult volunteers. Informed
consents were obtained before blood collection. The collec-
tion was monitored and approved by the local IRB from
Dexa Medica Group. The blood sample was put into 3.2%
sodium citrate solution in a 9:1 (v/v) ratio. Platelets were
isolatedbydiﬀerentialcentrifugationofblood(20minat100
× g) to obtain the platelet-rich plasma (PRP). The samples
were centrifuged again at 1600 × g for 10min and platelet-
poor plasma (PPP) was recovered from the supernatant
as a control. PRP was preincubated with DLBS1033 (5–
75mg/mL) for 60min at 37◦C. Platelet aggregation was
measured at 37◦C by light transmission using AggRam
platelet aggregation system (Helena Laboratories, PACK-4,
Beaumont, TX) with stirring rate of 600 rpm. The baseline
wasadjustedwithPPP.Atotalof250μLofsamplewasdrawn
using a pipette into an aggregation cuvette and incubated for
3min. The samples were then activated with 10μM ADP and
thrombin and platelet aggregation was recorded for 6min.
EDTA and Cilostazol were used as positive control.
2.2.3. Ex Vivo Antithrombosis Assay. Blood samples were
taken from healthy male volunteers after giving informed
consent. The DLBS1033 in various concentrations (50, 100,
and 200mg/mL) was used as sample and 20mM potassium
phosphate as blank. 250μL blank and 250μLs a m p l eo f
diﬀerent concentrations were mixed with 4μL thrombin
(0.92 IU) and 250μL fresh blood on a ceramic tile. Mixture
was incubated at 37◦C and coagulation of blood was
observed after 1h.
2.3. Thrombolytic Properties
2.3.1. Fibrin Plate Assay. The ﬁbrinolytic activity of
DLBS1033 was measured using ﬁbrin plate assay [15]w i t h
slight modiﬁcation on the amount of sample. 1% ﬁbrinogen
solution (Sigma) was prepared in 1x Phosphate buﬀer saline
(1x PBS). 10mL of the solution was distributed slowly into
each sterile petri dish (13cm). 12.5μL of 100U/μL thrombin
solution in 1x PBS was added into the plate and solidiﬁed for
30min at room temperature. Membrane discs were put on
the ﬁbrin plate surface. DLBS1033 (50mg/mL) was prepared
in 20mM phosphate buﬀer and 75μL aliquot was used as
sample. Sample and standard solutions were put separately
on membrane discs in the ﬁbrin plate. The plates were then
incubated at 37◦C and observed at 1, 2, 3, 4, 6, 8, 10, and
12h. The mean diameter of the hydrolyzed clear zone was4 Journal of Biomedicine and Biotechnology
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Figure 5: Activity of DLBS1033 on chromozym substrate. (a) Change in the absorbance at 405nm during assay of DLBS1033 with
chromozyme. (b) Linear section of changes in absorbance per one minute.
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Figure 6: Fibrinogen degradation by DLBS1033. Lane 1: ﬁbrino-
gen. Lanes 2–8 representing mixtures aliquot were taken at 0, 5, 15,
30, 45, 60, and 90 min, respectively.
measured and volume of lysis caused by DLBS1033 was then
calculated.
2.3.2. Clot Lysis Assay. Clot lysis assay was carried out
according to Prasad et al. [16]. Venous blood was drawn
from healthy volunteers after giving informed consent (n =
3). 500μL venous blood was put into pre-weighed sterile
microcentrifugetubeandincubatedat37◦Cfor60min.After
that, serum was removed from the blood clot. Phosphate
buﬀer 20mM as blank and 100μL of 50mg/mL DLBS1033
in phosphate buﬀer 20mM were added separately to the
clot and incubated at 37◦C for 120min. Fluid was removed
from the remaining clots and the tubes were weighed.
Thrombolytic activity was calculated by comparing the
initial weight of blood clot to that of lysed blood clot.
3. Results
3.1. Antithrombotic Properties
3.1.1. Fibrinogen Degradation Assay. The ﬁbrinogen hydrol-
ysispatternofDLBS1033wasobservedonα-,β-,andγ-chain
of ﬁbrinogen. The ﬁbrinogenolytic activity could be detected
within 5min (Figure 6). α-a n dγ-chain of ﬁbrinogen had
been completely degraded after 30min, except for the slight
β-chain that still remained until 90-min incubation. The fact
that the ﬁbrinogen chains were fully cleaved in a short time
indicated that DLBS1033 possessed strongerﬁbrinogenolytic
activity on α-a n dγ-chain than on β-chain.
3.1.2. Antiplatelet Aggregation Assay. I no r d e rt oo b s e r v e
the aggregation activity, thrombin and ADP were used in
this experiment as standard platelet aggregation activator.
Thrombin-induced platelet aggregation was reduced in
a dose-dependent manner when treated with DLBS1033.
DLBS1033 could totally inhibit the aggregation when its
concentration was more than 60mg/mL (Figure 7(a)).
Comparing to EDTA, when mixed with thrombin, it could
signiﬁcantly reduce the platelet aggregation by up to 95%.
Similar manner was observed in ADP-induced aggrega-
tion that had been treated with DLBS1033 (Figure 7(b)).
DLBS1033 could completely reduce platelet aggregation at
dose above 75mg/mL. As a comparison, cilostazol, when
mixed with ADP, could only reduce platelet aggregation by
15%, which was relatively insigniﬁcant.
In both cases, inhibition of aggregation was optimum at
a dose between 40 and 75mg/mL where DLBS1033 could
reduce more than 50% of the standard aggregation induced
by thrombin and ADP. This data suggests that DLBS1033 is a
strong antiplatelet aggregation agent.
3.1.3. Ex Vivo Antithrombotic Assay. DLBS1033 showed
antithrombotic inhibition activity by prolonging the blood
clotting time (Figure 8). In the ﬁrst 5 minutes, blood clot
had already been formed in the mixture with potassium
phosphate buﬀer as a blank, while no clot occurred when
treated with DLBS1033 in various concentrations. After 5
minutes, although blood clot had begun to form, including
in the sample receiving the highest concentration treatment,
the clot formation, took longer time with reduced clot
consistency. The result indicates that DLBS1033, in a dose-
dependent manner can prolong the clotting time and also,
reduce the consistency of clot as compared to that of the
blank.
3.2. Thrombolytic Properties
3.2.1. Fibrin Plate Assay. As evident in the formation of lysis
zone in ﬁbrin plate, DLBS1033 had degraded ﬁbrin intoJournal of Biomedicine and Biotechnology 5
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Figure 7: Inhibition of platelet aggregation by DLBS1033. Platelet aggregation induced by thrombin (a) and ADP (b) was downregulated by
the administration of DLBS1033. EDTA and cilostazol were used as the positive control.
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Figure 9: Volume of ﬁbrin lysed by DLBS1033 was calculated at
incubation time intervals.
soluble peptides, indicating its ﬁbrinolytic activity. The lysis
volume for each time interval was then calculated. Figure 9
shows that lysis volume could be quantiﬁed from the ﬁrst
hour of incubation period during which the volume kept
increasing until the 12th hour. This indicates that DLBS1033
possesses a fast and long-acting ﬁbrinolytic activity.6 Journal of Biomedicine and Biotechnology
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Figure10:LysisofbloodclotbyDLBS1033.Clotlysiswasmeasured
and compared between control and DLBS1033.
3.2.2. Clot Lysis Assay. The eﬀectiveness of DLBS1033 in
dissolving ﬁbrin in blood clot was then assayed using clot
lysisassay.TheeﬀectofDLBS1033inclotlysiswasobviousin
Figure 10. The amount of the blood lysed when treated with
DLBS1033 was 4-fold higher than that of the blank.
4. Discussion
The present study was performed to investigate the activities
of DLBS1033 as antithrombotic and thrombolytic agent.
Antithrombotic properties of DLBS1033 were ﬁrst assayed
on ﬁbrinogen which is one of the major components in
the coagulation pathway. Fibrinogen hydrolysis pattern con-
ferred by DLBS1033 was studied. During blood coagulation,
thrombin converts ﬁbrinogen to ﬁbrin monomers, which
associate into staggered, overlapping, 2-stranded ﬁbrils.
These 2-stranded ﬁbrils laterally associate to form ﬁbrin
bundles [17]. The three polypeptide chains of ﬁbrinogen
(α-66kd, β-54kd, and γ chain-48kd) [18]w e r ed e g r a d e d
in diﬀerent manners during incubation with DLBS1033
(Figure 6). The α-a n dγ-chain were completely degraded
ﬁrst, whereas the β-chain was slightly more resistant toward
degradation.
The degradation activity of DLBS1033 on the ﬁbrinogen
chains can decrease blood viscosity level, since blood vis-
cosity is correlated with ﬁbrinogen level in the blood [19].
The ﬁbrinogen α- chain is known to play an important role
in thrombin-induced ﬁbrin formation [20]. Moreover, γ-
chain of ﬁbrinogen reveals the main sites for interaction
with membrane receptor in the platelet [18], where the
aggregation process is mediated by binding of the ﬁbrinogen
t oap l a t e l e tc e l ls u r f a c er e c e p t o r ,g l y c o p r o t e i nI I b - I I I a[ 21].
Thus, the fast and complete degradation of α and γ-chain
may play a signiﬁcant role in performing antithrombotic
process. Our data showed that DLBS1033 degraded α and γ-
chain rapidly, indicating that DLBS1033 possesses eﬀective
antithrombotic activity.
DLBS1033 was shown to exhibit antiplatelet aggregation
activity which was induced by ADP and thrombin (Figures
7(a) and 7(b)). Platelets play a crucial role in thrombosis,
especially in arterial thrombosis and their pathologies [22].
The pharmacological mechanism of aggregation inhibition
was supposed to be eﬀectively performed by increasing
the cAMP level and inhibiting Ca transport as have been
reported previously [10].
The ex vivo coagulation model was studied using human
bloodinducedbythrombinwhichformedbloodclotswithin
2-hour observation. DLBS1033 was shown to prolong the
thrombus formation time (Figure 8). Thrombus formation
is inﬂuenced by the presence of thrombin which promotes
coagulation pathway activation [23]. The formation of
blood clot still occurred even with administration of high
concentration of DLBS1033, but with prolonged clotting
time. Furthermore, in this experiment, it was noticed that
the consistency of blood clot was also signiﬁcantly reduced
in a dose-dependent manner. The reduced clot consistency
might have occurred due to the eﬀect of digested γ-chain
of ﬁbrinogen which was important for stabilization of ﬁbrin
formation [18] or due to the ﬁbrinolytic activity of the
remaining DLBS1033 [19].
To further investigate the ﬁbrinolytic activity of
DLBS1033, the ﬁbrin plate assay was developed. DLBS1033
is a relatively fast and long-acting ﬁbrinolysis agent, where
the lysis zone in the ﬁbrin plate has already formed up
to quantiﬁable amount within 1-hour incubation, and its
ﬁbrinolysis activity still lasted up to 12 hours (Figure 9).
This ﬁnding was similar to previous results that earthworm
possessed direct activity toward ﬁbrin [4, 9].
The activity of DLBS1033 in the presence of thrombus
was then assessed by conducting clot lysis assay using
human blood clot, where the main protein component
is ﬁbrin. Weight of the clot before and after lysis was
considered as appropriate determinant of calculating clot
lysis percentage [16]. Other methods such as calculation
based on sample turbidity could not accurately determine
the clot lysed by DLBS1033 due to color of extract which
is yellow to brown and the low-molecular weight protein,
as well as other nonprotein components present in this
extract.Theresultshowedaremarkabledegradationofblood
clot by DLBS1033 compared to the control added only
with phosphate buﬀer (Figure 10). This indicates that the
degradation eﬀect of DLBS1033 towards human blood clot
is mainly due to its ﬁbrinolytic activity. The activity was
shown to be strong enough to penetrate into complex envi-
ronment of thrombus and resulted in the ﬁbrin degradation.
Therefore,DLBS1033mayserve asapromising thrombolytic
agent.
This present data indicates that DLBS1033, a unique
agent generated from Lumbricus rubellus earthworm pos-
sesses antithrombotic and thrombolytic activity. Antithrom-
botic activity is shown by its ﬁbrinogenolytic and antiplatelet
aggregation activities, whereas its thrombolytic activity is
exhibited by ﬁbrinolytic and blood clot lysis activities. In
addition, this agent had been proven safe without causing
any clinically severe adverse events during administration.
Therefore, DLBS1033 is suggested as a promising agent for
treating thrombus-related disease. Further studies are nec-
essary to investigate the characteristic activity of earthwormJournal of Biomedicine and Biotechnology 7
extract in facilitating blood circulation and also in other
diseases.
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